AngioDynamics (ANGO) Reports In-Line Q2 EPS; Trims FY16 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
AngioDynamics Reports Fiscal 2016 Second Quarter Results
January 7, 2016 4:01 PM ESTNet sales of $89.2 million GAAP loss of $0.01 per share; Non-GAAP adjusted EPS of $0.14Operating cash generation of $9.6 million
ALBANY, N.Y., Jan. 07, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today reported financial results for the second quarter of fiscal year 2016 ended November 30, 2015.
In the second quarter, we managed the business effectively, despite lingering headwinds, and... More
